Biozeus Completes Positive Phase II Trial in Women With FSIAD

Rio de Janeiro & London – October 2025 – Biozeus Biopharmaceuticals S.A. today announced positive topline results from its Phase II clinical trial evaluating BZ371A, a first-in-class therapeutic peptide for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD). The study met its primary endpoints, demonstrating statistically significant improvements in arousal and interest as well as broader measures of sexual function, with a favourable safety and tolerability profile. BZ371A is also in development for male sexual dysfunction, including patients recovering from radical prostatectomy, where early trials have shown superiority over existing standard of care. Strategic Transaction Biozeus has entered into an agreement to be acquired by Another Day Pharma Ltd. (ADP), a UK-based personal health innovation company. The acquisition, expected to close following ADP’s ongoing capital raise, will provide the resources and international platform to accelerate development and commercialisation of BZ371A globally. Next Steps Until completion of the transaction, Biozeus will continue to advance its clinical programme. Following close, ADP will lead global development, regulatory strategy, and future partnering discussions. About BZ371A BZ371A is a non-hormonal, non-CNS, topical therapeutic peptide that locally enhances nitric oxide synthase activity, promoting vasodilation and blood flow without systemic exposure. About Biozeus Biozeus Biopharmaceuticals S.A. is a Brazilian clinical-stage biotech developing a pipeline of therapeutic peptides for high-unmet-need indications. About Another Day Pharma Another Day Pharma Ltd. (www.anotherdaypharma.com) is a UK-based company focused on personal health innovation, building a portfolio of breakthrough therapeutics addressing major unmet needs in sexual health and beyond. Contacts Biozeus: [email protected] ADP: [email protected]

The release as fetched from its publisher. biozeus.com.br ↗